This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Endo receives India clearance to acquire domestic subsidiaries

By Freny Patel ( April 17, 2024, 01:44 GMT | Insight) -- US-based diversified healthcare company Endo Inc received clearance from the Indian antitrust watchdog to acquire 100 percent of the shares of its domestic subsidiaries, Endo India Holdings, Par Formulations, Par Active Technologies and Par Biosciences. The merger application was approved by the Competition Commission of India on Tuesday under the expedited green-channel route. The proposed transactions are being undertaken following a March 2024 order of the United States Bankruptcy Court, the parties informed the CCI. The specialty pharmaceutical company emerged from Chapter 11 bankruptcy with $2.5 billion in outstanding debt. US-based diversified healthcare company Endo Inc has received clearance from the Indian antitrust watchdog to acquire 100 percent of the shares of its domestic subsidiaries, Endo India Holdings, Par Formulations, Par Active Technologies and Par Biosciences....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login